Karyopharm Therapeutics Inc.
KPTI
$4.64
-$0.06-1.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 142.13M | 145.24M | 148.44M | 145.67M | 140.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 142.13M | 145.24M | 148.44M | 145.67M | 140.46M |
| Cost of Revenue | 4.59M | 6.01M | 16.72M | 15.75M | 8.59M |
| Gross Profit | 137.54M | 139.23M | 131.72M | 129.92M | 131.87M |
| SG&A Expenses | 113.24M | 115.44M | 118.94M | 122.11M | 125.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 261.07M | 264.68M | 274.41M | 276.62M | 272.86M |
| Operating Income | -118.94M | -119.44M | -125.97M | -130.95M | -132.40M |
| Income Before Tax | -62.50M | -76.37M | -87.18M | -89.63M | -146.00M |
| Income Tax Expenses | 22.00K | 57.00K | 296.00K | 280.00K | 340.00K |
| Earnings from Continuing Operations | -62.52 | -76.42 | -87.48 | -89.91 | -146.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.52M | -76.42M | -87.48M | -89.91M | -146.34M |
| EBIT | -118.94M | -119.44M | -125.97M | -130.95M | -132.40M |
| EBITDA | -118.61M | -119.10M | -125.63M | -130.61M | -132.08M |
| EPS Basic | -8.02 | -10.11 | -11.91 | -12.58 | -19.13 |
| Normalized Basic EPS | -8.05 | -9.35 | -10.45 | -10.87 | -11.93 |
| EPS Diluted | -13.34 | -15.42 | -17.19 | -17.82 | -19.19 |
| Normalized Diluted EPS | -7.70 | -9.00 | -10.10 | -10.53 | -11.93 |
| Average Basic Shares Outstanding | 33.26M | 32.49M | 31.75M | 31.05M | 30.59M |
| Average Diluted Shares Outstanding | 35.49M | 34.72M | 33.98M | 33.27M | 30.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |